FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Gilead's cash tender offer for CV Therapeutics, Inc. (Nasdaq:CVTX) has been terminated by the United States Federal Trade Commission prior to the expiration of the waiting period.
